A rash of failures for hepatitis C drugs, conflicting theories about the immune system's role and the looming issue of drug resistance make it impossible to predict when or how new therapies will make an impact. Ken Garber reports.
This is a preview of subscription content, log in via an institution to check access.
References
Lamarre, D. et al. Nature 426, 186–189 (2003).
Foy, E. et al. Science 300, 1145–1148 (2003).
Deveal, J. et al. Antimicrob. Agents Chemother. 51, 2920–2928 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Hepatitis C: staying the course. Nat Biotechnol 25, 1379–1381 (2007). https://doi.org/10.1038/nbt1207-1379
Issue Date:
DOI: https://doi.org/10.1038/nbt1207-1379
- Springer Nature America, Inc.
This article is cited by
-
Therapeutic Approaches for Zika Virus Infection of the Nervous System
Neurotherapeutics (2017)
-
Hepatitis C: move over interferon
Nature Biotechnology (2011)
-
Eukaryotic translation initiation machinery can operate in a bacterial-like mode without eIF2
Nature Structural & Molecular Biology (2008)